A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjögren\'s disease (SjD).
Epistemonikos ID: 1d48e7af54365ecf29bfdaec1a9a35cbef65019c
First added on: Oct 15, 2026